These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

165 related items for PubMed ID: 18283600

  • 21. Efficacy and tolerance of acne treatment using both spironolactone and a combined contraceptive containing drospirenone.
    Krunic A, Ciurea A, Scheman A.
    J Am Acad Dermatol; 2008 Jan; 58(1):60-2. PubMed ID: 17964689
    [Abstract] [Full Text] [Related]

  • 22. Comparative, open-label prospective study on the quality of life and sexual function of women affected by endometriosis-associated pelvic pain on 2 mg dienogest/30 µg ethinyl estradiol continuous or 21/7 regimen oral contraceptive.
    Caruso S, Iraci M, Cianci S, Fava V, Casella E, Cianci A.
    J Endocrinol Invest; 2016 Aug; 39(8):923-31. PubMed ID: 27023105
    [Abstract] [Full Text] [Related]

  • 23. Change to either a nonandrogenic or androgenic progestin-containing oral contraceptive preparation is associated with improved sexual function in women with oral contraceptive-associated sexual dysfunction.
    Davis SR, Bitzer J, Giraldi A, Palacios S, Parke S, Serrani M, Mellinger U, Nappi RE.
    J Sex Med; 2013 Dec; 10(12):3069-79. PubMed ID: 24034466
    [Abstract] [Full Text] [Related]

  • 24. Novel ethinyl estradiol-beta-cyclodextrin clathrate formulation does not influence the relative bioavailability of ethinyl estradiol or coadministered drospirenone.
    Blode H, Schürmann R, Benda N.
    Contraception; 2008 Mar; 77(3):171-6. PubMed ID: 18279686
    [Abstract] [Full Text] [Related]

  • 25. A combined oral contraceptive containing drospirenone changes neither endothelial function nor hemodynamic parameters in healthy young women: a prospective clinical trial.
    Giribela CR, Melo NR, Silva RC, Hong VM, Guerra GM, Baracat EC, Consolim-Colombo FM.
    Contraception; 2012 Jul; 86(1):35-41. PubMed ID: 22465116
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. YAZ and the novel progestin drospirenone.
    Mishell DR.
    J Reprod Med; 2008 Sep; 53(9 Suppl):721-8. PubMed ID: 18980044
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. A Canadian multicentre prospective study on the effects of an oral contraceptive containing 3 mg drospirenone and 30 microg ethinyl oestradiol on somatic and psychological symptoms related to water retention and on body weight.
    Endrikat J, Sandri M, Gerlinger C, Rübig A, Schmidt W, Fortier M.
    Eur J Contracept Reprod Health Care; 2007 Sep; 12(3):220-8. PubMed ID: 17763260
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Effect of an oral contraceptive containing ethinyl estradiol and drospirenone on premenstrual symptomatology and health-related quality of life.
    Borenstein J, Yu HT, Wade S, Chiou CF, Rapkin A.
    J Reprod Med; 2003 Feb; 48(2):79-85. PubMed ID: 12621790
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.